peripheral stem cell transplantation plus combination chemotherapy in treating patients with multiple myeloma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. purpose: phase ii trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy in treating patients who have multiple myeloma that has been treated for longer than 12 months.

objectives: i. evaluate the complete and partial response in multiple myeloma patients receiving peripheral blood stem cells supported by gemcitabine and high dose carmustine and melphalan followed by consolidation therapy with gemcitabine plus cyclophosphamide/dexamethasone/etoposide/cisplatin (dcep) and dexamethasone/paclitaxel/cisplatin. ii. evaluate the incidence of early death in comparison with historical data in this patient population. iii. evaluate the feasibility of chemotherapy with gemcitabine plus dcep and dexamethasone/paclitaxel/cisplatin following autotransplantation in these patients. outline: patients receive gemcitabine iv over 100 minutes on day -5 and again 6 hours after administration of carmustine iv over 2 hours on day -2, followed by melphalan iv over 20 minutes on day -1. patients receive intravenous cd34 peripheral blood stem cells on day 0. at 3 months and 9 months, patients with adequate hematologic counts receive cyclophosphamide iv, oral dexamethasone, etoposide iv, and cisplatin iv for 4 days. on day 3 of continuous infusions, gemcitabine is given over 100 minutes. at 6 and 12 months after autotransplant, patients receive oral dexamethasone on days 1-4, paclitaxel iv over 6 hours on day 2, and cisplatin iv over 24 hours on day 3. patients are followed every 6 weeks to 3 months until death. projected accrual: approximately 24-63 patients will be accrued within 2.5 years.

Eligibility criteria:
disease characteristics: histologically proven multiple myeloma with greater than 12 months of prior therapy bone marrow plasmacytosis at least 30% or protein criteria present no obvious myelodysplastic changes in the bone marrow no cns disease patient characteristics: age: 18 to 70 performance status: swog 0-2 (3-4 acceptable if based solely on bone pain) life expectancy: not specified hematopoietic: cd34+ at least 4,000/mm3 hepatic: bilirubin no greater than 1.5 mg/dl sgot or sgpt no greater than 4 times upper limit of normal no active or chronic hepatitis or liver cirrhosis renal: creatinine no greater than 3.0 mg/dl cardiovascular: lvef greater than 50% pulmonary: fev1 or fvc at least 50% of predicted dlco at least 50% of predicted patients unable to complete pulmonary function tests must have a ct scan of the chest and acceptable arterial blood gases of po2 greater than 70 other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception hiv negative no active infection requiring iv antibiotics prior concurrent therapy: biologic therapy: not specified chemotherapy: at least 4 weeks since prior chemotherapy endocrine therapy: prior steroid therapy allowed radiotherapy: at least 4 weeks since prior radiotherapy surgery: not specified

Keywords: refractory multiple myeloma stage i multiple myeloma stage ii multiple myeloma stage iii multiple myeloma